Clevidipine Stabilization via Light Blocking and Inert Atmosphere
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Clevidipine pharmaceutical compositions are prone to degradation due to light exposure and oxygen, leading to the formation of impurities such as H324/78, which compromises stability and potency.
Innovation Solution
Reducing light exposure and oxygen levels during manufacturing and storage by using light-blocking containers and replacing oxygen with inert gases like nitrogen, thereby minimizing oxidation reactions and maintaining the stability of clevidipine compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If clevidipine is exposed to light during manufacturing and storage, then the manufacturing and storage processes are simpler, but clevidipine degrades forming impurities such as H324/78
Solution Approach 1:
The patent applies the inert atmosphere principle by using light-blocking containers that create a protected environment during manufacturing and storage. The container material blocks light wavelengths that would otherwise cause clevidipine degradation, effectively creating an inert environment against photodegradation without requiring special lighting conditions or complex protective measures during processing.
2Adaptability or versatility
If oxygen is present during storage, then the storage conditions are less restrictive, but oxidation reactions occur reducing clevidipine potency
Solution Approach 1:
The patent replaces oxygen with an inert atmosphere by incorporating oxygen-scavenging materials or using containers flushed with inert gases like nitrogen. This creates an oxygen-free environment that prevents oxidation of clevidipine, maintaining drug potency without requiring stringent exclusion of atmospheric oxygen during storage and handling.
Solution Approach 2:
The patent uses oxygen-scavenging materials as intermediary substances that actively remove oxygen from the storage environment. These materials act as mediators between the clevidipine and atmospheric oxygen, preventing direct contact and oxidation reactions while allowing the drug to be stored under normal conditions.
3Stability of the object's composition
If light-blocking containers are used, then clevidipine stability is improved, but the container design becomes more complex
Solution Approach 1:
The patent applies the color changes principle by using containers with specific light-blocking properties, such as amber or brown glass, or plastics with appropriate UV absorbers. The container material is designed to block specific wavelengths of light that cause clevidipine degradation while maintaining transparency to other wavelengths, providing protection through material composition rather than complex structural design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively maintains the stability of clevidipine compositions, ensuring a ratio of clevidipine to H324/78 of at least 450:1, with detectable levels of H324/78 not exceeding 0.2%, thereby preserving the potency and shelf life of the pharmaceutical formulation.
Implementation Method 1
light can be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized
Implementation Method 2
reducing or preventing an oxidation reaction... placing the container into a secondary packaging that further reduces the amount clevidipine is exposed to light... replacing oxygen with nitrogen
Data Source
AI summary
Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed to oxygen and/or light during the manufacturing and storing processes. According to this method, oxygen must be removed or replaced, or light must be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized, such that the total detectable level of H324/78 in a given composition sample does not exceed about 0.2% on a weight-by-weight basis, or the ratio of clevidipine to H324/78 is equal to or greater than about 450 to 1 on a weight-to-weight basis.